Maggie Tabberer
Overview
Explore the profile of Maggie Tabberer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1374
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tabberer M, Williamson N, Tatlock S, Gater A, Grimes R, Akinseye C, et al.
J Patient Rep Outcomes
. 2024 Apr;
8(1):45.
PMID: 38641716
Background: Chronic obstructive pulmonary disease (COPD) and muscle weakness can cause impaired physical function, significantly impacting patients' health-related quality of life (HRQoL). Loss of muscle strength is usually assessed through...
2.
Fokkens W, Trigg A, Lee S, Chan R, Diamant Z, Hopkins C, et al.
J Patient Rep Outcomes
. 2023 Jan;
7(1):4.
PMID: 36662344
Background: Although the psychometric properties of patient-reported outcome measures (e.g. the 22-item Sino-nasal Outcomes Test [SNOT-22]) in chronic rhinosinusitis with nasal polyps (CRSwNP) have been defined, these definitions have not...
3.
Tabberer M, Wells J, Chandler D, Abetz-Webb L, Zhang S, Meeraus W, et al.
J Patient Rep Outcomes
. 2022 Nov;
6(1):117.
PMID: 36414789
Background: There is limited information available on the impact of moderate asthma exacerbations, often called "asthma attacks" (i.e., those not requiring hospitalisation or treatment with systemic corticosteroids) on patients' lives....
4.
Mohan D, Rossiter H, Watz H, Fogarty C, Evans R, Man W, et al.
Thorax
. 2022 Oct;
78(3):258-266.
PMID: 36283827
Background: Selective androgen receptor modulators (SARMs) increase muscle mass via the androgen receptor. This phase 2A trial investigated the effects of a SARM, GSK2881078, in conjunction with exercise, on leg...
5.
Tabberer M, Jones C, Kilbride S, Halpin D, Lomas D, Pascoe S, et al.
Adv Ther
. 2022 Jan;
39(3):1446.
PMID: 35060093
No abstract available.
6.
Thomashow B, Stiegler M, Criner G, Dransfield M, Halpin D, Han M, et al.
Chronic Obstr Pulm Dis
. 2021 Dec;
9(1):68-79.
PMID: 34972260
Background: In the InforMing the PAthway of COPD Treatment (IMPACT) trial, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) reduced moderate/severe exacerbation rates versus FF/VI and UMEC/VI in patients with chronic obstructive pulmonary disease...
7.
Tabberer M, von Maltzahn R, Bacci E, Karn H, Hsieh R, Howell T, et al.
J Patient Rep Outcomes
. 2021 Oct;
5(1):104.
PMID: 34632556
Background: Symptom constructs included in the Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS®: COPD) tool may be relevant to patients with asthma. The purpose of this study was...
8.
Fahy W, Homayoun-Valiani F, Cahn A, Robertson J, Templeton A, Meeraus W, et al.
Int J Chron Obstruct Pulmon Dis
. 2021 Jun;
16:1637-1646.
PMID: 34113095
Background: Management of acute exacerbations of chronic obstructive pulmonary disease (COPD) is sometimes inadequate leading to either prolonged duration and/or an increased risk of recurrent exacerbations in the period following...
9.
Halpin D, Worsley S, Ismaila A, Beeh K, Midwinter D, Kocks J, et al.
ERJ Open Res
. 2021 Jun;
7(2).
PMID: 34109236
Introduction: Real-world trial data comparing single- with multiple-inhaler triple therapy (MITT) in COPD patients are currently lacking. The effectiveness of once-daily single-inhaler fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) and MITT were...
10.
Llanos-Paez C, Ambery C, Yang S, Tabberer M, Beerahee M, Plan E, et al.
AAPS J
. 2021 Jun;
23(4):79.
PMID: 34080077
This study aimed to illustrate how a new methodology to assess clinical trial outcome measures using a longitudinal item response theory-based model (IRM) could serve as an alternative to mixed...